BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--()--The "BRAF Mutated Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted BRAF Mutated NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers. It can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.

There are several mutation associated with NSCLC but the most common are EGFR, KRAS, ROS-1, BRAF, BRAF, PD-L1 expression and others. Among all the mutations BRAF accounted for approximately 5% of the total cases of NSCLC.

BRAF mutated NSCLC is now recognized as a rare form of lung cancer. The biologic behavior of BRAF mutated lung tumors tends to be more aggressive. The one unique aspects of BRAF mutated NSCLC, which differentiates it from other molecularly driven tumors such as EGFR, ALK, and ROS1, is that patients with BRAF V600E-mutant NSCLC tend to be patients with a smoking history. The BRAF gene encodes for a serine/threonine kinase that belongs to the RAS-RAF-MEK-ERK axis that regulates cellular growth.

For diagnosis of mutation associated with NSCLC a laboratory test is done to check for certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. Molecular tests check for certain gene or chromosome changes that occur in NSCLC.

Report Highlights

  • 11-Year Forecast of BRAF mutated NSCLC epidemiology
  • 7MM Coverage
  • Total Incident Cases of NSCLC
  • Incident Cases according to segmentation: Histology, Stage, Genetic Mutation/Biomarker
  • Treated cases of NSCLC

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to BRAF mutated NSCLC?
  • What are the key findings pertaining to the BRAF mutated NSCLC epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of BRAF mutated NSCLC across the 7MM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of BRAF mutated NSCLC?

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global BRAF mutated NSCLC market
  • Quantify patient populations in the global BRAF mutated NSCLC market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for BRAF mutated NSCLC therapeutics in each of the markets covered
  • Understand the magnitude of BRAF mutated NSCLC population by its severity
  • The BRAF mutated NSCLC epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The BRAF mutated NSCLC Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Key Topics Covered:

 

1. Key Insights

 

2. Executive Summary of BRAF NSCLC Epidemiology

 

3. BRAF Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview

3.1. Introduction

3.1.1. Cellular Classification of NSCLC

3.1.2. Signs and Symptoms of NSCLC

3.1.3. Risk Factors of Lung Cancer

3.1.4. Causes of NSCLC

3.1.5. Disease Biology: NSCLC

 

4. Diagnosis of NSCLC

4.1. Diagnostic Algorithm for NSCLC

4.2. Stages of NSCLC

4.3. Staging System

 

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Total Incident cases of NSCLC patients in the 7MM

5.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM

5.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM

5.4. The United States Epidemiology

5.4.1. Total Incident cases of NSCLC patients in the United States

5.4.2. Total Incident cases of NSCLC patients by Histology in the United States

5.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States

5.4.4. Total Incident cases of BRAF Mutated NSCLC in the United States

 

6. EU-5 Epidemiology

6.1. Germany

6.2. France

6.3. Italy

6.4. Spain

6.5. The United Kingdom

 

7. Japan Epidemiology

 

8. Appendix

8.1. Bibliography

 

9. Report Methodology

 

10. Publisher Capabilities

 

11. Disclaimer

 

12. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/iu925k.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900